Recent News

• 11.05.2026 - Castle Biosciences Reports Third Quarter 2026 Results
• 10.28.2026 - Castle Biosciences to Participate in Upcoming Investor Conferences
• 10.15.2026 - Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
• 10.12.2026 - ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
• 09.30.2026 - Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
• 09.28.2026 - New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
• 09.24.2026 - New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
• 09.22.2026 - Castle Biosciences to Open New Laboratory Facility in Scottsdale
• 09.15.2026 - New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
• 09.09.2026 - JAAD Publication Shows Improved Performance of DecisionDx®-SCC

Recent Filings

• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - EX-99.1 EX-99.1
• 11.05.2026 - 8-K Current report
• 11.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.02.2026 - 144 Report of proposed sale of securities
• 10.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.29.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.14.2026 - 4 Statement of changes in beneficial ownership of securities